CY1118924T1 - Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας - Google Patents

Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας

Info

Publication number
CY1118924T1
CY1118924T1 CY20171100561T CY171100561T CY1118924T1 CY 1118924 T1 CY1118924 T1 CY 1118924T1 CY 20171100561 T CY20171100561 T CY 20171100561T CY 171100561 T CY171100561 T CY 171100561T CY 1118924 T1 CY1118924 T1 CY 1118924T1
Authority
CY
Cyprus
Prior art keywords
melatonin
treatment
autopath
agents
medicament
Prior art date
Application number
CY20171100561T
Other languages
English (en)
Inventor
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1118924(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals (1991) Limited filed Critical Neurim Pharmaceuticals (1991) Limited
Publication of CY1118924T1 publication Critical patent/CY1118924T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)

Abstract

Η εφεύρεση αφορά σε ένα φάρμακο, για τη θεραπεία και βελτίωση της αποκαταστιτικής ποιότητας του ύπνου, σε έναν ασθενή που πάσχει από πρωτοπαθή αϋπνία, το οποίο περιλαμβάνει τουλάχιστον ένα συστατικό που επιλέγεται από τη μελατονίνη, άλλους μελατονεργικούς παράγοντες, αγωνιστές της μελατονίνης και ανταγωνιστές της μελατονίνης, σε μια αποτελεσματική ποσότητα μέσα στο εύρος 0,0025 έως 50 mg, και προαιρετικά έναν ή περισσότερους θεραπευτικούς δραστικούς παράγοντες.
CY20171100561T 2001-08-14 2017-05-31 Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας CY1118924T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
PCT/IL2002/000662 WO2003015690A2 (en) 2001-08-14 2002-08-12 Method for treating primary insomnia

Publications (1)

Publication Number Publication Date
CY1118924T1 true CY1118924T1 (el) 2018-01-10

Family

ID=11075696

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100561T CY1118924T1 (el) 2001-08-14 2017-05-31 Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
CY20211100776T CY1124763T1 (el) 2001-08-14 2021-08-31 Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20211100776T CY1124763T1 (el) 2001-08-14 2021-08-31 Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας

Country Status (35)

Country Link
US (1) US8962024B2 (el)
EP (2) EP3103443B1 (el)
JP (1) JP2005501095A (el)
KR (1) KR20040032917A (el)
CN (1) CN100453078C (el)
AR (1) AR034975A1 (el)
AU (1) AU2002326114C1 (el)
BR (1) BR0211855A (el)
CA (1) CA2454699C (el)
CL (1) CL2002001701A1 (el)
CR (1) CR7271A (el)
CY (2) CY1118924T1 (el)
DK (2) DK1441702T3 (el)
EA (1) EA200400302A1 (el)
ES (2) ES2626591T3 (el)
GT (1) GT200200164A (el)
HU (1) HU230786B1 (el)
IL (1) IL144900A (el)
IS (1) IS3004B (el)
JO (1) JO3446B1 (el)
LT (1) LT1441702T (el)
MX (1) MXPA04001372A (el)
NO (1) NO334788B2 (el)
NZ (1) NZ531318A (el)
PA (1) PA8552301A1 (el)
PE (1) PE20030331A1 (el)
PL (1) PL367872A1 (el)
PT (2) PT1441702T (el)
PY (1) PY0218122A (el)
RU (1) RU2560840C2 (el)
SI (1) SI1441702T1 (el)
UA (1) UA87262C2 (el)
UY (1) UY27401A1 (el)
WO (1) WO2003015690A2 (el)
ZA (1) ZA200402005B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2008228903B2 (en) 2007-03-19 2013-03-07 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin B12
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
DK3337462T3 (da) 2016-10-31 2020-10-12 Neurim Pharma 1991 Melatonin-minitabletter og fremgangsmåde til fremstilling heraf

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378109B (el) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
SE378110B (el) 1972-05-19 1975-08-18 Bofors Ab
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) * 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IL105240A (en) 1992-04-07 1999-04-11 Neurim Pharma 1991 The use of melatonin in the preparation of a drug for the treatment of benign prostatic hyperplasia
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
WO1994013661A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Substituted pyrazoles as crf antagonists
ATE175961T1 (de) 1992-12-17 1999-02-15 Pfizer Pyrazole mit crf antagonistischer aktivität
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
AU7550994A (en) 1993-07-26 1995-02-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
AU3716997A (en) * 1996-07-17 1998-02-09 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) * 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
CZ299931B6 (cs) 2000-01-05 2008-12-29 Neurim Pharmaceuticals (1991) Ltd. Prípravek na lécbu rezistence vuci antihypertenzivum a podobných stavu a jeho použití
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
US6703412B1 (en) * 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
CN103974741A (zh) 2011-09-27 2014-08-06 Ibis医药股份有限公司 胃内植入装置

Also Published As

Publication number Publication date
IL144900A (en) 2013-12-31
CN100453078C (zh) 2009-01-21
CL2002001701A1 (es) 2010-06-25
WO2003015690B1 (en) 2004-03-11
EP1441702A4 (en) 2007-09-26
IS7136A (is) 2004-01-30
PT1441702T (pt) 2017-06-02
WO2003015690A2 (en) 2003-02-27
DK3103443T3 (da) 2021-08-30
HUP0401042A2 (hu) 2004-08-30
RU2560840C2 (ru) 2015-08-20
ES2626591T3 (es) 2017-07-25
IS3004B (is) 2018-09-15
ES2882584T3 (es) 2021-12-02
CA2454699A1 (en) 2003-02-27
HK1066161A1 (zh) 2005-03-18
DK1441702T3 (en) 2017-06-06
KR20040032917A (ko) 2004-04-17
NO20040087L (no) 2004-02-19
AU2002326114B2 (en) 2007-03-08
LT1441702T (lt) 2017-06-12
AR034975A1 (es) 2004-03-24
SI1441702T1 (sl) 2017-08-31
ZA200402005B (en) 2005-07-27
US8962024B2 (en) 2015-02-24
CY1124763T1 (el) 2022-07-22
UY27401A1 (es) 2003-02-28
CN1541092A (zh) 2004-10-27
JP2005501095A (ja) 2005-01-13
JO3446B1 (ar) 2020-07-05
WO2003015690A3 (en) 2003-09-25
AU2002326114C1 (en) 2019-03-21
PE20030331A1 (es) 2003-06-27
CR7271A (es) 2004-05-17
PY0218122A (es) 2004-03-01
NO334788B1 (no) 2014-05-26
EA200400302A1 (ru) 2004-10-28
US20040248966A1 (en) 2004-12-09
NO334788B2 (no) 2014-05-26
NZ531318A (en) 2005-08-26
EP3103443A1 (en) 2016-12-14
HU230786B1 (en) 2018-05-02
EP3103443B1 (en) 2021-06-30
PT3103443T (pt) 2021-08-12
UA87262C2 (uk) 2009-07-10
MXPA04001372A (es) 2005-06-06
PL367872A1 (en) 2005-03-07
EP1441702A2 (en) 2004-08-04
IL144900A0 (en) 2002-06-30
BR0211855A (pt) 2004-09-21
PA8552301A1 (es) 2003-06-30
CA2454699C (en) 2012-03-27
AU2002326114A1 (en) 2003-03-03
HUP0401042A3 (en) 2009-07-28
EP1441702B1 (en) 2017-05-10
GT200200164A (es) 2003-09-26
RU2011131532A (ru) 2013-03-27

Similar Documents

Publication Publication Date Title
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
CY1112689T1 (el) Συνθεση για τη βελτιωση της γνωσης και της μνημης
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1107586T1 (el) Θepαπεiα για τη δυσκοιλιoτητα
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
EA200500782A1 (ru) Лечение геморрагического шока
NO990912L (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav
DK0998287T3 (da) Anvendelse af levobupivacain
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
NO20004419D0 (no) Ny anvendelse
SE9704644D0 (sv) New use
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
CO4230161A1 (es) Compuestos neuroprotectores que bloquean los receptores de aminoacidos excitativos y antiisquemicos
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
DE50214008D1 (de) Arzneimittel zur behandlung von tumoren und deren metastasen unter verwendung eines bindemoleküls gegen das bone-sialoprotein
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
DE69732492D1 (de) Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden